
We are…Believers in the Extraordinary.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer.
Learn more about why we are fueled by our beliefs in science, patients, and in our people
We are…Believers in the Extraordinary.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer.
Learn more about why we are fueled by our beliefs in science, patients, and in our people

Believers in Science.
Extraordinary persistence, grit, and unwavering passion drive our commitment to the delivery of scientific innovation. We harness that passion to discover, develop, and investigate novel and potentially life-changing cancer therapies in disease areas with high unmet need.
Learn More About Our Pipeline
Believers in Science.
Extraordinary persistence, grit, and unwavering passion drive our commitment to the delivery of scientific innovation. We harness that passion to discover, develop, and investigate novel and potentially life-changing cancer therapies in disease areas with high unmet need.
Learn More About Our Pipeline

Believers in Patients.
It’s the strength of patients that fuels our work. It pushes us to learn, quickly refine and double down where it counts the most.
Learn More About Patients Who Inspire Us
Believers in Patients.
It’s the strength of patients that fuels our work. It pushes us to learn, quickly refine and double down where it counts the most.
Learn More About Patients Who Inspire Us

Believers in Our People.
If you want to do something that matters, this work matters. Patients drive our passion to pioneer novel therapies. That’s why we’ve built an environment centered around support, flexibility, and a shared mission.
Learn what it’s like to be part of our team
Believers in Our People.
If you want to do something that matters, this work matters. Patients drive our passion to pioneer novel therapies. That’s why we’ve built an environment centered around support, flexibility, and a shared mission.
Learn what it’s like to be part of our team

Karyopharm Clinical Trials
Karyopharm has ongoing clinical trials for our lead drug candidate and next-generation programs in earlier lines of treatment, in combination trials, and in a variety of tumor types across both hematologic and solid tumors.
Learn More About Our Clinical Trials
Karyopharm Clinical Trials
Karyopharm has ongoing clinical trials for our lead drug candidate and next-generation programs in earlier lines of treatment, in combination trials, and in a variety of tumor types across both hematologic and solid tumors.
Learn More About Our Clinical Trials

XPO1 Inhibition & SINE Technology
Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis. Oncogenesis is the process through which healthy cells become transformed into cancer cells.
Learn More About Our Technology
XPO1 Inhibition & SINE Technology
Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis. Oncogenesis is the process through which healthy cells become transformed into cancer cells.
Learn More About Our Technology
Tweets
Press Releases
March 3, 2025
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 24, 2025
Karyopharm Announces 1-for-15 Reverse Stock Split
February 19, 2025
Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress
Investor Events
Wednesday, February 19, 2025
8:00am – 9:00am EST
8:00am – 9:00am EST
Karyopharm Therapeutics 4Q24 Earnings Call
Tuesday, December 3, 2024
11:30am EST
11:30am EST
Piper Sandler 36th Annual Healthcare Conference
Tuesday, November 5, 2024
8:00am – 9:00am EST
8:00am – 9:00am EST
Karyopharm Therapeutics 3Q24 Earnings Call
Thursday, October 31, 2024
8:00am – 9:00am EDT
8:00am – 9:00am EDT
Karyopharm Therapeutics Phase 3 SENTRY Trial Update
